Gossamer Bio CDO Caryn Peterson Receives Equity Award

What Happened

• Caryn Peterson, Chief Development Officer of Gossamer Bio, was granted 5,800,051 derivative shares on 2026-08-24. The grant is reported at an acquisition price of $0.00 (Form 4 transaction code A — grant/award), so no cash changed hands at grant. This is a compensation equity award, not an open-market purchase or sale.

Key Details

• Transaction date and filing: grant dated August 24, 2026; Form 4 filed August 26, 2026.
• Grant amount and price: 5,800,051 shares, $0.00 per share (derivative award).
• Shares owned after transaction: Not specified in the provided filing data.
• Vesting/performance conditions (per footnote F1): 50% of the total grant vests upon FDA approval of seralutinib; the remaining 50% vests in 1/24th increments monthly after such approval, subject to continuous service. If FDA approval does not occur within two years of the grant date, then 1/24th of the total grant will vest monthly starting at the two-year anniversary, subject to continuous service.
• Filing timeliness: Form 4 filed two days after the transaction date (Aug 26 for Aug 24 transaction), which is within the usual two-business-day reporting window.

Context

• This is a contingent, performance- and service-based equity award (derivative) rather than a cash purchase or sale. Such grants are commonly used for executive compensation and align pay with product milestones (here, FDA approval of seralutinib).
• Because no shares were bought or sold on the open market and the award vests on specific conditions, the grant does not indicate an immediate change in Peterson’s cash exposure or a direct market signal.